Novozymes

Advances in Digitalization Presented at the 10th Annual Genedata Biopharma Partner Symposium

Retrieved on: 
Jeudi, mars 21, 2024
AbbVie, Peptide, ChromeOS, Automation, Sanofi, Organization, Canadian Aviation Regulations, AstraZeneca, Novo Nordisk, MAM, Novartis, GSK, Boehringer Ingelheim, UCB, Vivisection, Roche, NGS, RNA, Knowledge, Merck, Hyphen, Spacecraft, Janssen, Daiichi Sankyo, Digitization, Novozymes, Fine chemical

BASEL, Switzerland, March 21, 2024 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the successful conclusion of the 10th Annual Genedata Biopharma Partner Symposium, held over 2 days from March 6–7, 2024 in Basel, Switzerland. This year's event marked the tenth year of bringing together Genedata customers to share best practices and demonstrate how they increase efficiency and productivity across entire organizations by leveraging the Genedata Biopharma Platform.

Key Points: 
  • BASEL, Switzerland, March 21, 2024 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the successful conclusion of the 10th Annual Genedata Biopharma Partner Symposium, held over 2 days from March 6–7, 2024 in Basel, Switzerland.
  • The Genedata Biopharma Partner Symposium has firmly established itself as a community platform to exchange pioneering work in digitalizing biopharma R&D and establishing best practices based on the Genedata software platform.
  • "The Genedata Biopharma Partner Symposium has firmly established itself as a community platform to exchange pioneering work in digitalizing biopharma R&D and establishing best practices based on the Genedata software platform.
  • The record participation this year underscores the leading position of the Genedata Biopharma Platform within the biopharma industry," said Othmar Pfannes, Ph.D., CEO of Genedata.

2023 Novo Holdings Bioindustrial Investments Team Annual Review/Business Update

Retrieved on: 
Vendredi, mars 15, 2024
Health, Biotechnology, Agriculture, Fungus, Biofuel, Climate, Novo, Investment, CHR, Partnership, Novozymes

Made substantial investments, solidifying Novo Holdings' position as one of the world's foremost active investors in the bioindustrial sector.

Key Points: 
  • Made substantial investments, solidifying Novo Holdings' position as one of the world's foremost active investors in the bioindustrial sector.
  • COPENHAGEN, Denmark, March 15, 2024 /PRNewswire/ -- Novo Holdings Bioindustrial Investments team today publishes its review of 2023 – paving the way for a more sustainable future.
  • Novo Holdings Bioindustrial Investments team understands that radical innovation is needed if we are to win the battle against global warming and its damaging effects on the health of people and the planet.
  • The Bioindustrial Investments team remains steadfast on harnessing the power of biotechnology to deliver impactful solutions for both industry and agriculture.

2023 Novo Holdings Bioindustrial Investments Team Annual Review/Business Update

Retrieved on: 
Vendredi, mars 15, 2024
Health, Biotechnology, Agriculture, Fungus, Biofuel, Climate, Novo, Investment, CHR, Partnership, Novozymes

Made substantial investments, solidifying Novo Holdings' position as one of the world's foremost active investors in the bioindustrial sector.

Key Points: 
  • Made substantial investments, solidifying Novo Holdings' position as one of the world's foremost active investors in the bioindustrial sector.
  • COPENHAGEN, Denmark, March 15, 2024 /PRNewswire/ -- Novo Holdings Bioindustrial Investments team today publishes its review of 2023 – paving the way for a more sustainable future.
  • Novo Holdings Bioindustrial Investments team understands that radical innovation is needed if we are to win the battle against global warming and its damaging effects on the health of people and the planet.
  • The Bioindustrial Investments team remains steadfast on harnessing the power of biotechnology to deliver impactful solutions for both industry and agriculture.

Meatable Strengthens Board of Directors to Accelerate Growth of Breakthrough Food Technology

Retrieved on: 
Jeudi, février 15, 2024
Technology, Retail, Food Tech, Food, Beverage, DSM, Research, Master of Science, Biotechnology, Multimedia, Chemistry, Food technology, University, Liberty Media, General partnership, TSX, McGill University, Marketing, Columbia Business School, Syngenta, MBA, Plural, Meat, Health, CAD, Mood Media, FUN Technologies, Toxicology, Science, Food security, Biology, Novozymes, Development, Head, Management

“Meatable is at an exciting juncture in our growth trajectory as we prepare to launch our consumer products in Singapore and host our first tasting in the EU.

Key Points: 
  • “Meatable is at an exciting juncture in our growth trajectory as we prepare to launch our consumer products in Singapore and host our first tasting in the EU.
  • On the Meatable Board, Mr. Abony will support the company’s management team by advising on commercial development initiatives in the U.S. as well as future transactions.
  • “Compared to others in its category, Meatable is highly differentiated through its industry-first technology and phased approach.
  • “Meatable is working at the forefront of food technology and is a clear-cut leader in the cultivated meat space,” said Ms. Malarkey.

Legacy Novozymes delivers solid last full-year results

Retrieved on: 
Jeudi, février 1, 2024
Growth, Annual report, COVID-19, Drink, Nutrition, CHR, Novozymes, Health, Geography, Bank statement

Legacy Novozymes is delivering solid growth and earnings in a year characterized by changing market demands, with 6% organic sales growth in Q4 and 5% organic sales growth in 2023.

Key Points: 
  • Legacy Novozymes is delivering solid growth and earnings in a year characterized by changing market demands, with 6% organic sales growth in Q4 and 5% organic sales growth in 2023.
  • This marks the last financial reporting from legacy Novozymes, and the new company, Novonesis, is already a reality.
  • In the 2023 financial year, legacy Novozymes delivers 5% organic sales growth – 6% organic sales growth in the fourth quarter alone – an EBIT-margin before special items[*] of 25.4%, and ROIC including goodwill before special items* of 16.5%.
  • “Legacy Novozymes has leveraged its strengths of a well-diversified portfolio, unique production capabilities, and broad market presence to deliver strong growth in a volatile market.

The combination of Novozymes and Chr. Hansen is now successfully completed, creating Novonesis – a leading global biosolutions partner

Retrieved on: 
Lundi, janvier 29, 2024
Pro forma, Capital market, Biology, Foodservice, Energy, Science, PPA, CHR, EPS, Plant, Novozymes, Agriculture, Novo, Growth

Hansen entered into an agreement to create a leading global biosolutions partner through a statutory merger of the two companies.

Key Points: 
  • Hansen entered into an agreement to create a leading global biosolutions partner through a statutory merger of the two companies.
  • Ester Baiget, President and CEO of Novonesis, says:
    We have successfully combined Novozymes and Chr.
  • Hansen and today we come together as one leading global biosolutions partner.
  • Hansen will create a leading global biosolutions partner with a broad biological toolbox and a diversified portfolio in attractive markets.

Marine Enzymes Market to increase by USD 54.62 million from 2023 to 2028, Advanced Enzyme Technologies Ltd., Air Liquide SA, Antozyme Biotech Pvt. Ltd., and more among key companies- Technavio

Retrieved on: 
Jeudi, décembre 14, 2023
Medicine, Carbohydrate, Drink, BASF SE, Food, USD, BASF, Cosmetics, Lipase, Plasticizer, Geography, Novo Nordisk, Growth, Novozymes, ASA, SE, SEPPIC, Enzyme, Free, Fine chemical

NEW YORK, Dec. 14, 2023 /PRNewswire/ -- The marine enzymes market is expected to grow by USD 54.62 million from 2023 to 2028.

Key Points: 
  • NEW YORK, Dec. 14, 2023 /PRNewswire/ -- The marine enzymes market is expected to grow by USD 54.62 million from 2023 to 2028.
  • Growing demand for food enzymes is notably driving the marine enzymes market.
  • However, factors such as the complex production process of marine enzymes may impede market growth.
  • We provide a detailed analysis of 20 companies operating in the marine enzymes market including Advanced Enzyme Technologies Ltd., Air Liquide SA, Antozyme Biotech Pvt.

Microbial Agricultural Inoculants Market to increase by USD 243.73 million between 2023 to 2028, AquaBella Organic Solutions LLC, BASF SE, Bayer AG and more among key companies - Technavio

Retrieved on: 
Vendredi, décembre 8, 2023
Agriculture, Seed, Bacillus firmus, BASF SE, IAB, Bayer, Fungus, BIO, Biology, Corteva, USD, Farmer, BASF, Novozymes, Pesticide, SE, FREE, Emergent BioSolutions, Wine, Plant, Geography

NEW YORK, Dec. 8, 2023 /PRNewswire/ -- The microbial agricultural inoculants market size is expected to grow by USD 243.73 million from 2023 to 2028.

Key Points: 
  • NEW YORK, Dec. 8, 2023 /PRNewswire/ -- The microbial agricultural inoculants market size is expected to grow by USD 243.73 million from 2023 to 2028.
  • Rising concerns over the use of chemical fertilizers and pesticides in agriculture are notably driving the microbial agricultural inoculants market.
  • However, factors such as a lack of awareness of microbial agricultural inoculants among farmers may impede market growth.
  • Microbial Agricultural Inoculants Market 2024-2028: Company Analysis
    BASF SE - The company offers microbial agricultural inoculants such as Poncho Votivo bio seeds made up of Bacillus microbial and Votivo prime made up of Bacillus firmus microbial, under its brand called BioSolutions.

Novozymes launches Quara® LowP for renewable diesel feedstock pre-treatment

Retrieved on: 
Jeudi, novembre 9, 2023
Ester, Aviation biofuel, Water, Hydrotreated vegetable oil, HVO, Novozymes, SAF, Dicarboxylic acid, Renewable energy, Jet fuel

Novozymes, a global leader in biosolutions, marks a significant milestone in the renewable diesel and SAF (Sustainable Aviation Fuel) industry with the launch of Quara® LowP, an enzymatic solution designed to transform the feedstock pre-treatment process.

Key Points: 
  • Novozymes, a global leader in biosolutions, marks a significant milestone in the renewable diesel and SAF (Sustainable Aviation Fuel) industry with the launch of Quara® LowP, an enzymatic solution designed to transform the feedstock pre-treatment process.
  • As the world seeks sustainable alternatives to traditional fuels, renewable diesel and SAF production have taken center stage.
  • By 2030, vegetable oils are projected to account for over 40% of global feedstock used in renewable diesel and SAF production.
  • For more information about Quara LowP and Novozymes' biosolutions for renewable diesel feedstocks, please visit https://www.novozymes.com/en/solutions/renewable-diesel .

Michael Burns Joins Invizyne as Executive Vice President of Energy Transition

Retrieved on: 
Mercredi, novembre 8, 2023
Carbon, Bryant University, Energy transition, U.S. Department of Energy, Office of Inspector General, Bio Products Laboratory, Enzyme, BASF, Aviation, Nature Communications, Western New England University, U.S. Department of Defense Strategy for Operating in Cyberspace, Synthetic biology, Verenium Corporation, MDB, Renewable energy, Novozymes

Monrovia, CA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc. , a leading designer of enzyme-based biomanufacturing systems – and a subsidiary of MDB Capital Holdings, LLC , (NASDAQ:MDBH) ("MDB") ­– today announced the appointment of Michael Burns to its senior leadership team as Executive Vice President, Energy Transition.

Key Points: 
  • Monrovia, CA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc. , a leading designer of enzyme-based biomanufacturing systems – and a subsidiary of MDB Capital Holdings, LLC , (NASDAQ:MDBH) ("MDB") ­– today announced the appointment of Michael Burns to its senior leadership team as Executive Vice President, Energy Transition.
  • "Michael Burns brings two decades worth of business strategy and development, global licensing, project development, and project finance expertise in the sustainable energy and synthetic biology industries to Invizyne.
  • We are honored to have an executive with his gravitas and experience join the team to head up our new Energy Transition business unit,” said Mo Hayat, CEO of Invizyne.
  • He also served in strategy and development roles at Verenium Corporation, a specialized enzyme biotechnology company that was acquired by BASF.